Heron (HRTX) EVP William Forbes Receives 3,874 Shares via RSU Vesting

What Happened
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics (HRTX), had 3,874 restricted stock units convert to common shares (reported as exercise/conversion of a derivative) on July 19, 2026. To satisfy tax withholding, 1,101 of those shares were withheld at $0.47 per share (total withholding reported as $517), leaving a net of 2,773 shares issued to him. The filings show the conversion/exercise entries as $0.00 proceeds, indicating these were vested RSUs converted to stock rather than a cash sale.

Key Details

• Transaction date: 2026-07-19; Form 4 filed 2026-07-20.
• Reported entries: M (exercise/conversion of derivative) — 3,874 shares; F (tax withholding) — 1,101 shares withheld at $0.47 ($517).
• Net shares received: 2,773 (3,874 vested − 1,101 withheld).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes: F1 — each RSU converts to one share; F2 — RSUs vest in 16 equal quarterly installments beginning 01/19/2024.
• No 10b5-1 plan, gift, or sale reported; this appears to be routine RSU vesting with tax-withholding.

Context

• This is a routine equity-compensation event (RSU vesting) rather than an open-market purchase or a sale. The withholding of shares to cover taxes is common and does not necessarily indicate a change in insider sentiment.
• For retail investors: vested RSUs increase insider ownership but are standard compensation; purchases are generally more informative about bullishness than routine vesting.